FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157222208> ?p ?o ?g. }

• W3157222208 abstract "Introduction Crohn’s disease (CD) is a chronic inflammatory bowel disease with a heterogeneous clinical presentation, relapse rate and treatment response. At present, no markers are available to adequately predict disease course at diagnosis. To prevent overtreatment of patients with a relative mild disease course, a step-up approach starting with corticosteroids is usually applied. Timely introduction of potentially disease modifying drugs and tight control of mucosal inflammation are crucial to prevent disease-related complications in patients with a complex disease course. We hypothesise that episodic treatment with adalimumab monotherapy in combination with close monitoring after drug discontinuation improves long-term outcome and reduces drug-related side effects, while preventing overtreatment. Methods and analysis In this pragmatic multicentre randomised controlled trial, newly diagnosed CD patients or CD patients with a flare, naïve to thiopurines and biologicals, will be included and randomised 1:1 to open-label episodic (ie, 24 weeks) adalimumab monotherapy or step-up care starting with corticosteroids. The primary outcome is the number of yearly quarters of corticosteroid free clinical (Monitor Inflammatory Bowel Disease At Home score ≤3) and biochemical (C reactive protein within normal range and faecal calprotectin ≤200 µg/g) remission at week 96. Secondary outcomes are total healthcare costs, cumulative corticosteroid dose, proportion of patients with endoscopic remission at week 24, corticosteroid-free clinical remission, time to remission and patient-reported outcome measures on quality of life, (work) disability and treatment adherence. Safety outcomes are drug-related and disease-related adverse events and disease progression on MRI-enterography at week 96. Ethics and dissemination This study is approved by the Medical Research Ethics Committee of azM/UM in Maastricht dated 21 August 2019 (METC18-076) and is monitored by the Clinical Trial Centre Maastricht according to Good Clinical Practice guidelines. Written informed consent will be obtained from all patients. Study results will be published in international peer-reviewed medical journals. Trial registration number NCT03917303 ." @default.
• W3157222208 created "2021-05-10" @default.
• W3157222208 creator A5007717321 @default.
• W3157222208 creator A5010781248 @default.
• W3157222208 creator A5021404933 @default.
• W3157222208 creator A5024673070 @default.
• W3157222208 creator A5028518564 @default.
• W3157222208 creator A5035560892 @default.
• W3157222208 creator A5037713519 @default.
• W3157222208 creator A5058784327 @default.
• W3157222208 creator A5064799727 @default.
• W3157222208 creator A5082075359 @default.
• W3157222208 creator A5086914025 @default.
• W3157222208 creator A5088510584 @default.
• W3157222208 date "2021-05-01" @default.
• W3157222208 modified "2023-09-27" @default.
• W3157222208 title "Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial" @default.
• W3157222208 cites W1964225748 @default.
• W3157222208 cites W1977158732 @default.
• W3157222208 cites W2056586250 @default.
• W3157222208 cites W2071662837 @default.
• W3157222208 cites W2079528157 @default.
• W3157222208 cites W2126807394 @default.
• W3157222208 cites W2129558176 @default.
• W3157222208 cites W2144550346 @default.
• W3157222208 cites W2149309054 @default.
• W3157222208 cites W2152381563 @default.
• W3157222208 cites W2169467558 @default.
• W3157222208 cites W2188248802 @default.
• W3157222208 cites W2334353679 @default.
• W3157222208 cites W2335600129 @default.
• W3157222208 cites W2507736693 @default.
• W3157222208 cites W2523706394 @default.
• W3157222208 cites W2559823888 @default.
• W3157222208 cites W2591958845 @default.
• W3157222208 cites W2605466240 @default.
• W3157222208 cites W2734356183 @default.
• W3157222208 cites W2750760542 @default.
• W3157222208 cites W2766230215 @default.
• W3157222208 cites W2900579574 @default.
• W3157222208 cites W2953285235 @default.
• W3157222208 cites W2981768636 @default.
• W3157222208 doi "https://doi.org/10.1136/bmjopen-2020-042885" @default.
• W3157222208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8098960" @default.
• W3157222208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33947729" @default.
• W3157222208 hasPublicationYear "2021" @default.
• W3157222208 type Work @default.
• W3157222208 sameAs 3157222208 @default.
• W3157222208 citedByCount "0" @default.
• W3157222208 crossrefType "journal-article" @default.
• W3157222208 hasAuthorship W3157222208A5007717321 @default.
• W3157222208 hasAuthorship W3157222208A5010781248 @default.
• W3157222208 hasAuthorship W3157222208A5021404933 @default.
• W3157222208 hasAuthorship W3157222208A5024673070 @default.
• W3157222208 hasAuthorship W3157222208A5028518564 @default.
• W3157222208 hasAuthorship W3157222208A5035560892 @default.
• W3157222208 hasAuthorship W3157222208A5037713519 @default.
• W3157222208 hasAuthorship W3157222208A5058784327 @default.
• W3157222208 hasAuthorship W3157222208A5064799727 @default.
• W3157222208 hasAuthorship W3157222208A5082075359 @default.
• W3157222208 hasAuthorship W3157222208A5086914025 @default.
• W3157222208 hasAuthorship W3157222208A5088510584 @default.
• W3157222208 hasBestOaLocation W31572222081 @default.
• W3157222208 hasConcept C126322002 @default.
• W3157222208 hasConcept C168563851 @default.
• W3157222208 hasConcept C187212893 @default.
• W3157222208 hasConcept C197934379 @default.
• W3157222208 hasConcept C203092338 @default.
• W3157222208 hasConcept C2776760755 @default.
• W3157222208 hasConcept C2777138892 @default.
• W3157222208 hasConcept C2778260677 @default.
• W3157222208 hasConcept C2778292693 @default.
• W3157222208 hasConcept C2778715236 @default.
• W3157222208 hasConcept C2779134260 @default.
• W3157222208 hasConcept C2779280984 @default.
• W3157222208 hasConcept C2780132546 @default.
• W3157222208 hasConcept C2780479503 @default.
• W3157222208 hasConcept C71924100 @default.
• W3157222208 hasConceptScore W3157222208C126322002 @default.
• W3157222208 hasConceptScore W3157222208C168563851 @default.
• W3157222208 hasConceptScore W3157222208C187212893 @default.
• W3157222208 hasConceptScore W3157222208C197934379 @default.
• W3157222208 hasConceptScore W3157222208C203092338 @default.
• W3157222208 hasConceptScore W3157222208C2776760755 @default.
• W3157222208 hasConceptScore W3157222208C2777138892 @default.
• W3157222208 hasConceptScore W3157222208C2778260677 @default.
• W3157222208 hasConceptScore W3157222208C2778292693 @default.
• W3157222208 hasConceptScore W3157222208C2778715236 @default.
• W3157222208 hasConceptScore W3157222208C2779134260 @default.
• W3157222208 hasConceptScore W3157222208C2779280984 @default.
• W3157222208 hasConceptScore W3157222208C2780132546 @default.
• W3157222208 hasConceptScore W3157222208C2780479503 @default.
• W3157222208 hasConceptScore W3157222208C71924100 @default.
• W3157222208 hasFunder F4320321007 @default.
• W3157222208 hasLocation W31572222081 @default.
• W3157222208 hasLocation W31572222082 @default.
• W3157222208 hasLocation W31572222083 @default.
• W3157222208 hasOpenAccess W3157222208 @default.
• W3157222208 hasPrimaryLocation W31572222081 @default.
• W3157222208 hasRelatedWork W1963997208 @default.

• next